Try our beta test site

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01015118
First received: November 9, 2009
Last updated: October 14, 2016
Last verified: October 2016
  Purpose
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

Condition Intervention Phase
Ovarian Neoplasms
Peritoneal Neoplasms
Drug: Placebo
Drug: Paclitaxel
Drug: BIBF 1120
Drug: Carboplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria. [ Time Frame: First drug administration to date of disease progression or death whichever occurs first, upto 29 months ]

    Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment.

    Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.



Secondary Outcome Measures:
  • PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint) [ Time Frame: First drug administration to date of disease progression or death whichever occurs first, upto 29 months ]

    Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1.

    Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.


  • Overall Survival [ Time Frame: First drug administration until data cut-off 29Apr2013, upto 41 months ]

    Overall survival is defined as time from randomization until death.

    Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

    This study is ongoing, thus overall survival data is immature at this stage of primary analysis.


  • Time to CA-125 Tumour Marker Progression [ Time Frame: First drug administration until data cut-off 29Apr2013, upto 41 months ]
    Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 >=2 x nadir in case nadir value > ULN or CA-125 >=2 x ULN in case nadir value <= ULN.

  • Objective Response Based on Investigator Assessment [ Time Frame: First drug administration until data cut-off 29Apr2013, upto 41 months ]
    Objective tumour response defined as either complete response [CR] or partial response [PR] in patients with at least 1 target lesion reported at baseline

  • Change in Abdominal/Gastro-intestinal Symptoms Over Time [ Time Frame: First drug administration until data cut-off 29Apr2013, upto 41 months ]

    Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28).

    As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology).

    Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB−III vs IV), and Carboplatin level (AUC5 vs. AUC6).


  • Change in Global Health Status/ Quality of Life (QoL) Scale Over Time. [ Time Frame: First drug administration until data cut-off 29Apr2013, upto 41 months ]

    Change in Global Health Status/ QoL over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure.

    As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning).

    Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB−III vs IV), and Carboplatin level (AUC5 vs. AUC6).



Enrollment: 1366
Study Start Date: November 2009
Study Completion Date: September 2016
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120
patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
Drug: BIBF 1120
comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
Drug: Paclitaxel
Paclitaxel (standard chemo-therapy)
Drug: Carboplatin
Carboplatin (standard chemo-therapy)
Placebo Comparator: Placebo
patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
Drug: Placebo
comparator to BIBF 1120
Drug: Paclitaxel
Paclitaxel (standard chemo-therapy)
Drug: Carboplatin
Carboplatin (standard chemo-therapy)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • first diagnosis of histologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  • International Federation of Gynecology and Obstetrics (FIGO) Stages IIB - IV
  • females, age 18 years or older
  • life expectancy of at least 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • prior surgery, defined as either (a) debulking surgery with maximum surgical effort at cytoreduction with the goal of no residual disease or (b) biopsy or limited surgery in patients with stage IV disease for whom surgical debulking was not considered appropriate, if diagnosis is confirmed by histology and no surgery is planned prior to disease progression (including interval debulking surgery)
  • patient has given written informed consent which must be consistent with the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local legislation
  • planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery

Exclusion criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum
  • planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery
  • clinically relevant non-healing wound, ulcer or bone fracture
  • clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration
  • brain metastases
  • pre-existing sensory or motor neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher, except due to trauma
  • history of major thromboembolic event
  • known inherited or acquired bleeding disorder
  • significant cardiovascular diseases
  • clinically relevant pericardial effusion
  • history of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months
  • inadequate safety laboratory values
  • serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)
  • poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer
  • prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy)
  • prior systemic cytotoxic chemotherapy
  • prior treatment with BIBF 1120 or any other angiogenesis inhibitor
  • prior radiotherapy
  • serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration
  • Women of childbearing potential who are sexually active and not using a highly effective method of birth control during the trial and for at least twelve months after the end of active therapy.
  • pregnancy or breast feeding
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • active alcohol or drug abuse
  • patients unable to comply with the protocol
  • any contraindications for therapy with paclitaxel or carboplatin
  • treatment with other investigational drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01015118

  Hide Study Locations
Locations
United States, Arizona
Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
United States, California
Boehringer Ingelheim Investigational Site
Long Beach, California, United States
Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
United States, Colorado
Boehringer Ingelheim Investigational Site
Englewood, Colorado, United States
United States, Connecticut
Boehringer Ingelheim Investigational Site
New Haven, Connecticut, United States
United States, Florida
Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
United States, Georgia
Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
United States, Kentucky
Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
United States, Louisiana
Boehringer Ingelheim Investigational Site
Marrero, Louisiana, United States
United States, Michigan
Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
United States, Minnesota
Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
United States, New York
Boehringer Ingelheim Investigational Site
New York, New York, United States
United States, North Carolina
Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
United States, North Dakota
Boehringer Ingelheim Investigational Site
Bismark, North Dakota, United States
United States, Ohio
Boehringer Ingelheim Investigational Site
Canton, Ohio, United States
Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
United States, Oregon
Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
Boehringer Ingelheim Investigational Site
Abington, Pennsylvania, United States
Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
United States, Rhode Island
Boehringer Ingelheim Investigational Site
Providence, Rhode Island, United States
United States, South Carolina
Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
United States, Tennessee
Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
United States, Texas
Boehringer Ingelheim Investigational Site
Austin, Texas, United States
Boehringer Ingelheim Investigational Site
Bedford, Texas, United States
Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
Boehringer Ingelheim Investigational Site
Houston, Texas, United States
United States, Washington
Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
Boehringer Ingelheim Investigational Site
Vancouver, Washington, United States
Australia, New South Wales
Boehringer Ingelheim Investigational Site
Camperdown, New South Wales, Australia
Boehringer Ingelheim Investigational Site
Waratah, New South Wales, Australia
Australia, Queensland
Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
Boehringer Ingelheim Investigational Site
Southe Brisbane, Queensland, Australia
Australia, South Australia
Boehringer Ingelheim Investigational Site
North Terrace, South Australia, Australia
Australia, Victoria
Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
Australia, Western Australia
Boehringer Ingelheim Investigational Site
Nedlands, Western Australia, Australia
Austria
Boehringer Ingelheim Investigational Site
Graz, Austria
Boehringer Ingelheim Investigational Site
Innsbruck, Austria
Boehringer Ingelheim Investigational Site
Krems, Austria
Boehringer Ingelheim Investigational Site
Kufstein, Austria
Boehringer Ingelheim Investigational Site
Linz, Austria
Boehringer Ingelheim Investigational Site
Salzburg, Austria
Boehringer Ingelheim Investigational Site
Wels, Austria
Boehringer Ingelheim Investigational Site
Wien, Austria
Belgium
Boehringer Ingelheim Investigational Site
Edegem, Belgium
Boehringer Ingelheim Investigational Site
Hasselt, Belgium
Boehringer Ingelheim Investigational Site
La Louvière, Belgium
Boehringer Ingelheim Investigational Site
Leuven, Belgium
Boehringer Ingelheim Investigational Site
Liège, Belgium
Boehringer Ingelheim Investigational Site
Sint-Niklaas, Belgium
Canada, British Columbia
Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Canada, Ontario
Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
Boehringer Ingelheim Investigational Site
London, Ontario, Canada
Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Boehringer Ingelheim Investigational Site
Sherbrooke, Quebec, Canada
Czech Republic
Boehringer Ingelheim Investigational Site
Brno, Czech Republic
Boehringer Ingelheim Investigational Site
Olomouc, Czech Republic
Boehringer Ingelheim Investigational Site
Prague, Czech Republic
Denmark
Boehringer Ingelheim Investigational Site
Aalborg, Denmark
Boehringer Ingelheim Investigational Site
Herlev, Denmark
Boehringer Ingelheim Investigational Site
Herning, Denmark
Boehringer Ingelheim Investigational Site
Købenahvn Ø, Denmark
Boehringer Ingelheim Investigational Site
Odense C, Denmark
Finland
Boehringer Ingelheim Investigational Site
Helsinki, Finland
Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
Boehringer Ingelheim Investigational Site
Kuopio, Finland
Boehringer Ingelheim Investigational Site
Oulu, Finland
Boehringer Ingelheim Investigational Site
Tampere, Finland
France
Boehringer Ingelheim Investigational Site
Aix-en-Provence, France
Boehringer Ingelheim Investigational Site
Avignon cedex 02, France
Boehringer Ingelheim Investigational Site
Besançon, France
Boehringer Ingelheim Investigational Site
Bordeaux cedex, France
Boehringer Ingelheim Investigational Site
Bordeaux, France
Boehringer Ingelheim Investigational Site
Caen cedex 5, France
Boehringer Ingelheim Investigational Site
Clermont-Ferrand cedex, France
Boehringer Ingelheim Investigational Site
Dechy, France
Boehringer Ingelheim Investigational Site
Fréjus, France
Boehringer Ingelheim Investigational Site
La Roche-Sur-Yon cedex 09, France
Boehringer Ingelheim Investigational Site
Le Mans, France
Boehringer Ingelheim Investigational Site
Lille cedex, France
Boehringer Ingelheim Investigational Site
Lyon, France
Boehringer Ingelheim Investigational Site
Marseille cedex 09, France
Boehringer Ingelheim Investigational Site
Monaco cedex, France
Boehringer Ingelheim Investigational Site
Mont-de-Marsan cedex, France
Boehringer Ingelheim Investigational Site
Montpellier cedex 5, France
Boehringer Ingelheim Investigational Site
Mougins, France
Boehringer Ingelheim Investigational Site
Nancy, France
Boehringer Ingelheim Investigational Site
Nantes cedex 02, France
Boehringer Ingelheim Investigational Site
Orléans cedex 02, France
Boehringer Ingelheim Investigational Site
Paris cedex 20, France
Boehringer Ingelheim Investigational Site
Paris, France
Boehringer Ingelheim Investigational Site
PERIGUEUX Cedex, France
Boehringer Ingelheim Investigational Site
Plerin Sur Mer, France
Boehringer Ingelheim Investigational Site
Saint Cloud, France
Boehringer Ingelheim Investigational Site
Saint-Herblain cedex, France
Boehringer Ingelheim Investigational Site
Strasbourg cedex, France
Boehringer Ingelheim Investigational Site
Thonon-Les-Bains, France
Boehringer Ingelheim Investigational Site
Vandoeuvre les Nancy cedex, France
Boehringer Ingelheim Investigational Site
Villejuif Cedex, France
Germany
Boehringer Ingelheim Investigational Site
Aachen, Germany
Boehringer Ingelheim Investigational Site
Aalen, Germany
Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
Boehringer Ingelheim Investigational Site
Berlin, Germany
Boehringer Ingelheim Investigational Site
Bonn, Germany
Boehringer Ingelheim Investigational Site
Bottrop, Germany
Boehringer Ingelheim Investigational Site
Böblingen, Germany
Boehringer Ingelheim Investigational Site
Chemnitz, Germany
Boehringer Ingelheim Investigational Site
Dessau, Germany
Boehringer Ingelheim Investigational Site
Detmold, Germany
Boehringer Ingelheim Investigational Site
Dresden, Germany
Boehringer Ingelheim Investigational Site
Düsseldorf, Germany
Boehringer Ingelheim Investigational Site
Ebersberg, Germany
Boehringer Ingelheim Investigational Site
Essen, Germany
Boehringer Ingelheim Investigational Site
Frankfurt, Germany
Boehringer Ingelheim Investigational Site
Freiburg, Germany
Boehringer Ingelheim Investigational Site
Freudenstadt, Germany
Boehringer Ingelheim Investigational Site
Fulda, Germany
Boehringer Ingelheim Investigational Site
Fürstenfeldbruck, Germany
Boehringer Ingelheim Investigational Site
Greifswald, Germany
Boehringer Ingelheim Investigational Site
Gütersloh, Germany
Boehringer Ingelheim Investigational Site
Halle/S., Germany
Boehringer Ingelheim Investigational Site
Hamburg, Germany
Boehringer Ingelheim Investigational Site
Hanau, Germany
Boehringer Ingelheim Investigational Site
Heidelberg, Germany
Boehringer Ingelheim Investigational Site
Henstedt-Ulzburg, Germany
Boehringer Ingelheim Investigational Site
Hildesheim, Germany
Boehringer Ingelheim Investigational Site
Karlsruhe, Germany
Boehringer Ingelheim Investigational Site
Kiel, Germany
Boehringer Ingelheim Investigational Site
Krefeld, Germany
Boehringer Ingelheim Investigational Site
Landshut, Germany
Boehringer Ingelheim Investigational Site
Ludwigsburg, Germany
Boehringer Ingelheim Investigational Site
Lübeck, Germany
Boehringer Ingelheim Investigational Site
Magdeburg, Germany
Boehringer Ingelheim Investigational Site
Mainz, Germany
Boehringer Ingelheim Investigational Site
Mannheim, Germany
Boehringer Ingelheim Investigational Site
Marburg, Germany
Boehringer Ingelheim Investigational Site
München, Germany
Boehringer Ingelheim Investigational Site
Neumarkt i.d.Opf., Germany
Boehringer Ingelheim Investigational Site
Offenbach, Germany
Boehringer Ingelheim Investigational Site
Paderborn, Germany
Boehringer Ingelheim Investigational Site
Radebeul, Germany
Boehringer Ingelheim Investigational Site
Ravensburg, Germany
Boehringer Ingelheim Investigational Site
Regensburg, Germany
Boehringer Ingelheim Investigational Site
Rosenheim, Germany
Boehringer Ingelheim Investigational Site
Rostock, Germany
Boehringer Ingelheim Investigational Site
Saalfeld, Germany
Boehringer Ingelheim Investigational Site
Salzgitter, Germany
Boehringer Ingelheim Investigational Site
Solingen, Germany
Boehringer Ingelheim Investigational Site
Stadthagen, Germany
Boehringer Ingelheim Investigational Site
Stendal, Germany
Boehringer Ingelheim Investigational Site
Stralsund, Germany
Boehringer Ingelheim Investigational Site
Stuttgart, Germany
Boehringer Ingelheim Investigational Site
Suhl, Germany
Boehringer Ingelheim Investigational Site
Traunstein, Germany
Boehringer Ingelheim Investigational Site
Trier, Germany
Boehringer Ingelheim Investigational Site
Tübingen, Germany
Boehringer Ingelheim Investigational Site
Ulm, Germany
Boehringer Ingelheim Investigational Site
Viersen, Germany
Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
Boehringer Ingelheim Investigational Site
Witten, Germany
Boehringer Ingelheim Investigational Site
Wolfsburg, Germany
Boehringer Ingelheim Investigational Site
Worms, Germany
Greece
Boehringer Ingelheim Investigational Site
Athens, Greece
Boehringer Ingelheim Investigational Site
Heraklio, Greece
Boehringer Ingelheim Investigational Site
Nea Kifisia, Greece
Boehringer Ingelheim Investigational Site
Patras, Greece
Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
Italy
Boehringer Ingelheim Investigational Site
Asti, Italy
Boehringer Ingelheim Investigational Site
Avellino, Italy
Boehringer Ingelheim Investigational Site
Aviano (pn), Italy
Boehringer Ingelheim Investigational Site
Bari, Italy
Boehringer Ingelheim Investigational Site
Benevento, Italy
Boehringer Ingelheim Investigational Site
Brescia, Italy
Boehringer Ingelheim Investigational Site
Catania, Italy
Boehringer Ingelheim Investigational Site
Catanzaro, Italy
Boehringer Ingelheim Investigational Site
Faenza (ra), Italy
Boehringer Ingelheim Investigational Site
Ferrara, Italy
Boehringer Ingelheim Investigational Site
Genova, Italy
Boehringer Ingelheim Investigational Site
Lecce, Italy
Boehringer Ingelheim Investigational Site
Mantova, Italy
Boehringer Ingelheim Investigational Site
Meldola (fc), Italy
Boehringer Ingelheim Investigational Site
Milano, Italy
Boehringer Ingelheim Investigational Site
Modena, Italy
Boehringer Ingelheim Investigational Site
Monza, Italy
Boehringer Ingelheim Investigational Site
Napoli, Italy
Boehringer Ingelheim Investigational Site
Padova, Italy
Boehringer Ingelheim Investigational Site
Palermo, Italy
Boehringer Ingelheim Investigational Site
Pisa, Italy
Boehringer Ingelheim Investigational Site
Pordenone, Italy
Boehringer Ingelheim Investigational Site
Reggio Emilia, Italy
Boehringer Ingelheim Investigational Site
Roma, Italy
Boehringer Ingelheim Investigational Site
Rozzano (MI), Italy
Boehringer Ingelheim Investigational Site
San Fermo Della Battaglia, Italy
Boehringer Ingelheim Investigational Site
Sondrio, Italy
Boehringer Ingelheim Investigational Site
Tappino (cb), Italy
Boehringer Ingelheim Investigational Site
Torino, Italy
Boehringer Ingelheim Investigational Site
Varese, Italy
Netherlands
Boehringer Ingelheim Investigational Site
's-HERTOGENBOSCH, Netherlands
Boehringer Ingelheim Investigational Site
Amersfoort, Netherlands
Boehringer Ingelheim Investigational Site
Niewegein, Netherlands
Boehringer Ingelheim Investigational Site
Nijmegen, Netherlands
Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
Norway
Boehringer Ingelheim Investigational Site
Bergen, Norway
Boehringer Ingelheim Investigational Site
Oslo, Norway
Boehringer Ingelheim Investigational Site
Stavanger, Norway
Boehringer Ingelheim Investigational Site
Trondheim, Norway
Poland
Boehringer Ingelheim Investigational Site
Gdansk, Poland
Boehringer Ingelheim Investigational Site
Lublin, Poland
Boehringer Ingelheim Investigational Site
Warszawa, Poland
Portugal
Boehringer Ingelheim Investigational Site
Coimbra, Portugal
Boehringer Ingelheim Investigational Site
Lisboa, Portugal
Boehringer Ingelheim Investigational Site
Porto, Portugal
Boehringer Ingelheim Investigational Site
Vila Real, Portugal
Russian Federation
Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
Boehringer Ingelheim Investigational Site
Kazan, Russian Federation
Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Slovakia
Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
Boehringer Ingelheim Investigational Site
Kosice, Slovakia
Boehringer Ingelheim Investigational Site
Nitra, Slovakia
Boehringer Ingelheim Investigational Site
Poprad, Slovakia
Boehringer Ingelheim Investigational Site
Zilina, Slovakia
Spain
Boehringer Ingelheim Investigational Site
Badalona, Spain
Boehringer Ingelheim Investigational Site
Barcelona, Spain
Boehringer Ingelheim Investigational Site
Girona, Spain
Boehringer Ingelheim Investigational Site
Lleida, Spain
Boehringer Ingelheim Investigational Site
Madrid, Spain
Boehringer Ingelheim Investigational Site
Palma de Mallorca, Spain
Boehringer Ingelheim Investigational Site
Valencia, Spain
Sweden
Boehringer Ingelheim Investigational Site
Linköping, Sweden
Boehringer Ingelheim Investigational Site
Lund, Sweden
Boehringer Ingelheim Investigational Site
Stockholm, Sweden
Boehringer Ingelheim Investigational Site
Umeå, Sweden
Boehringer Ingelheim Investigational Site
Uppsala, Sweden
Ukraine
Boehringer Ingelheim Investigational Site
Cherkasy, Ukraine
Boehringer Ingelheim Investigational Site
Dnepropetrovsk, Ukraine
Boehringer Ingelheim Investigational Site
Donetsk, Ukraine
Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
Boehringer Ingelheim Investigational Site
Lviv, Ukraine
United Kingdom
Boehringer Ingelheim Investigational Site
Derby, United Kingdom
Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
Boehringer Ingelheim Investigational Site
Guildford, United Kingdom
Boehringer Ingelheim Investigational Site
London, United Kingdom
Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
Boehringer Ingelheim Investigational Site
Poole, United Kingdom
Boehringer Ingelheim Investigational Site
Truro, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01015118     History of Changes
Other Study ID Numbers: 1199.15  AGO-OVAR12  2008-006831-10 
Study First Received: November 9, 2009
Results First Received: November 14, 2014
Last Updated: October 14, 2016

Additional relevant MeSH terms:
Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Paclitaxel
Nintedanib
Albumin-Bound Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors

ClinicalTrials.gov processed this record on February 27, 2017